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Two major types of amyloidosis are primary amyloidosis or amyloid light chain amyloidosis and secondary
amyloidosis. Although amyloidosis involves a variety of organ systems including skin, the occurrence of bullous skin
lesions is rare. Little is known about the mechanism of blister formation. These blisters are often hemorrhagic and
typically occur in the oral mucosa. Only a few case reports have described skin involvement in systemic amyloidosis.
The manifestation of bullous lesions on the breast in association with primary amyloidosis has not been previously
reported. Therefore, we report a case of cutaneous hemorrhagic bullous of the breast secondary to primary systemic
amyloidosis, which may be important for medical oncologists to be aware of this uncommon presentation of plasma
cell dysrasias. Furthermore, this case only partially responded to the commonly used multiple myeloma-type
regimen, the skin lesions responded completely to a five-drug combination chemotherapy regimen, utilizing
immunomodulators, liposomal doxorubicin, cyclophosphamide, bortezomib, and dexamethasone, suggesting that a
more aggressive modality of chemotherapy may be necessary to treat such cases.Background
Primary and secondary amyloidosis are the two major
types of amyloidosis. The primary systemic amyloidosis,
also known as light chain (AL) amyloidosis, is mostly
related to a plasma cell dyscrasia. The secondary (AA)
amyloidosis is derived from serum amyloid A subunit
protein, an acute-phase protein that is produced in re-
sponse to inflammatory conditions [1]. There is no iden-
tifiable, underlying cause of AL amyloidosis [2]. The
fibrils of AL amyloidosis are composed of polymerized
immunoglobulin light chain or light chain fragments [3].
Amyloid protein is resistant to proteolysis and has a
three dimensional configuration as a beta pleated sheet
[4]. Although cutaneous involvement in primary* Correspondence: jcwang5@aol.com
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reproduction in any medium, provided the orsystemic amyloidosis is relatively common [5], the oc-
currence of bullous skin lesions is rare [2,3].
Only a few cases of cutaneous involvement with sys-
temic light chain amyloidosis have been reported in the lit-
erature. Skin involvement in the form of hemorrhagic
bullous is much rarer. To the best of our knowledge,
hemorrhagic bullous presentation of amyloidosis on the
breast skin has not been reported in the literature. This
uncommon presentation of amyloidosis was only partially
responsive to the commonly used combination chemo-
therapy regimens, but it responded completely to a five-
drug combination regimen. This suggests that a more ag-
gressive approach, with combination of multiple immuno-
modulators and chemotherapy agents may be required to
achieve a meaningful response in similar cases.Case report
A 51-year-old African American female with no signifi-
cant past medical history presented in April 2009 with aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 A hematoxylin and eosin stained section
demonstrates collections of dull eosinophilic fissured material
within the dermis consistent with amyloid, which, on Congo
red stain, showed apple-green birefringence in polarized light
and confirmed amyloid deposits (not shown).
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breasts. The patient had no other symptoms. She was
not taking any medication, and her social and family his-
tories were noncontributory. Physical examination
revealed extensive bullous ulcerating and hemorrhagic
skin lesions involving posterior aspects of both breasts
and upper abdominal skin bilaterally (Figure 1). An ini-
tial diagnostic skin biopsy of the skin lesion revealed
abundant amyloid deposits with positive congo red stain
and positive apple-green birefringence under polarized
light microscopy. These findings were consistent with
pathologic diagnosis of bullous amyloidosis of skin
(Figure 2). A direct immunofluorescence study of the
specimen with a panel of four immunoglobulins (IgG,
IgA, IgM, and C3) was negative. No circulating anti-
body against basement membrane zone antibody was
detected by indirect immunofluorescence study. Initial
hematologic workup included serum protein electro-
phoresis, which had a normal pattern without any M-
spike in the gamma region; serum immunofixation was
negative for any monoclonal gammopathy, and quanti-
tative immunoglobulin assay was consistent with mild
panhypogammaglobulinemia. However, a serum-free
light chain assay revealed a very high level of kappa
light chain of 6090 mg/dl and lambda light chain of
0.05 mg/dL; urine light chain assay was confirmatory
with a very high level of kappa light chain of
6220 mg/dl. The patient also had a mild, normochro-
mic, normocytic anemia with hemoglobin of 11.2 g/dl
and normal red blood cell indices. Bone marrowFigure 1 Extensive hemorrhagic bullae with desquamation and
surrounding purpura in skin of both breasts, prior to
treatment.aspiration and biopsy showed infiltration of the mar-
row with a monoclonal population of plasma cells,
comprising 50% of total cells. Flow cytometry of an
aspirated bone marrow specimen yielded a monoclonal
population of CD138 positive, IgG κ plasma myeloma
cells. Conventional cytogenetic examination showed a
normal female karyotype of 46 XX; however, FISH was
positive for monosomy of chromosome 13 (loss of
both RB1 and LAMP1) in 10.3% of cells, and t [6,7],
indicating overexpression of BCL1, and cyclin D1
(CCND1/IGH) rearrangement in 5.8% of the cells.
Bone survey revealed multiple lytic bone lesions, in-
cluding the left greater femoral trochanter, right hu-
meral head, and T12 vertebral bodies. Therefore, a
diagnosis of bullous hemorrhagic skin lesions, asso-
ciated with primary systemic light chain amyloidosis
was made.
The patient was initially treated with an RVD regimen,
which included a combination of bortezomib, with a
dose of 1.3 mg/m2 on days 1, 4, 8, 11, plus lenalidomide,
with dose of 25 mg daily on days 1–14, and dexametha-
sone, with a dose of 40 mg twice a week, repeated on
every 21 days cycles for a total of four cycles. This unfor-
tunately resulted in only a partial response, which
included some improvement of the skin lesions and re-
duction of kappa light chain only to 2250 mg/dl (PR, as
per NCCN guideline; more than 50% reduction in the
serum free light chain levels). Because of significant per-
sistent skin lesions, a search for enrolling the patient in
a clinical trial was attempted; unfortunately, there was
none available at the time. Therefore, a more aggressive
treatment plan was initiated. This was included a com-
bination of liposomal doxorubicin, with a dose of
40 mg/m2 on day one, cyclophosphamide, with a dose of
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1.3 mg/m2, on days 1, 8, and 15, lenalidomide , 15 mg
daily on days 1–21 , and dexamethasone, with a dose of
40 mg twice a week, repeated on every 28 days cycles
for a total of six cycles. This treatment resulted in a very
good partial response rate, with significant reduction of
the kappa light chain to 208 mg/dl after two cycles of
treatment (VGPR, as per NCCN guidelines; more than
90% reduction in the serum free light chain levels). Con-
tinuation of the above regimen for a total of six cycles
resulted in further reduction of kappa light chain to
114 mg/dl and complete disappearance of hemorrhagic
bullous skin lesions (Figure 3). It is important to men-
tion that although skin rashes are common in the
patients treated with lenalidomide, this patient did not
report any such adverse side effects with the treatment.
The patient was then successfully consolidated with
high dose chemotherapy, followed by autologous hema-
topoietic stem cell transplantation. She has been followed
closely, and she has continued to be in complete remis-
sion (CR) up to the date of this report.
Discussion
Bullous pemphigoid (and linear IgA disease) is a hetero-
geneous group of autoimmune blistering disorders of
the subepiderm and is associated with autoantibodies,
predominantly IgG, against the transmembrane hemi-
desmosomal protein BP180/type XVII collagen [8]. Mu-
cous membrane pemphigoid is characterized byFigure 3 Complete resolution of skin lesions, Post-therapy.subepithelial separation and deposition of immunoglo-
bulins and complement along the basement membrane
zone. This disease is diagnosed with direct immuno-
fluorescence testing showing a linear deposition of
immunoglobulins and/or complement along the base-
ment membrane zone and indirect immunofluorescence
testing showing circulating IgG (and sometimes IgA)
autoantibodies along the basement membrane zone [9].
Light chain (AL) amyloidosis is a plasma cell dyscra-
sia characterized by the pathologic production and de-
position of monoclonal light chain fibrillar proteins in
tissues, resulting in organ dysfunction. The goal of
treatment of AL amyloidosis is eradication of the
monoclonal plasma cell population and suppression of
the pathologic levels of light chains. The use of novel
agents, such as thalidomide, lenalidomide and bortezo-
mib alone or in combination with steroids and alkylat-
ing agents has shown efficacy and continues to be
explored [10]. HevyLite™ is a new, recently developed
method that facilitates separate quantification of the
kappa and lambda-bounded amounts of a given im-
munoglobulin. This new assay provides precise quanti-
fication of heavy and light chain and their ratio of the
involved immunoglobulin more accurately than the
other currently available methods; moreover, they carry
prognostic information regarding survival in multiple
myeloma patients [11].
Primary systemic amyloidosis, a disease characterized by
infiltration of different organs [4], and associated amy-
loidosis cause clinically detectable cutaneous changes in
approximately 10-40% of patients [5]; The occurrence
of bullous skin lesions, however, is rare [2,3]. The bullae
may be intradermal or subepidermal [2]. The bullae
form of cutaneous amyloidosis results from cleavage of
the amyloid deposits. These blisters are often
hemorrhagic and most commonly occur in the oral mu-
cosa [5].
In this reported case, skin lesions did not reveal im-
munoglobulin deposits, and indirect immunofluores-
cence staining for basement membrane protein was
negative. Skin biopsy showed positive congo red stain-
ing, and amyloid deposits were identified with a positive
apple-green birefringence under polarized light micros-
copy. These findings, along with bone marrow infiltra-
tion by abundant plasma cells, multiple lytic bone
lesions, and the presence of light chain protein, con-
firmed a diagnosis of bullous skin lesion secondary to
primary systemic amyloidosis.
Insufficient data are available in the literature for the
optimal treatment of amyloidosis with underlying
plasma cell disorder; therefore, most treatment strategies
used in systemic light chain amyloidosis are derived
from multiple myeloma regimens. Intermediate or high-
dose melphalan followed by stem cell transplantation is
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Comprehensive Cancer Network panel. In some cases,
AL amyloidosis is considered to be a treatable disease,
and a substantial proportion of patients now attain a
long survival; a 22% survival rate of more than 10 years
has been reported by Gertz et al. [4]. Treating systemic
AL amyloidosis has recently evolved with the use of au-
tologous stem cell transplantation and the introduction
of the newer thalidomide analogue. The thalidomide
analog, lenalidomide, and the proteasome inhibitor, bor-
tezomib, are both active in advanced and refractory mul-
tiple myeloma. The ability of these drugs in combination
with dexamethasone to rapidly reduce the level of the
monoclonal protein is being examined in several clinical
trials. However, this option may not be applicable to all
cases, especially those involving hemorrhagic bullous
amyloidosis (Table 1). Multiple different single-agent or
combination regimens have been used with variable
responses, mostly unsatisfactory. Steroids and alkylating
agents and even the CHOP regimen (cyclophosphamide,
hydroxydaunomycin, Oncovin, and prednisone) have
been used as part of the treatment. Lenalidomide is an
appealing therapeutic option for subjects with advanced
AL amyloidosis and refractory to both melphalan and
bortezomib [12].Table 1 Summary of the therapeutic regimens used for the tr
amyloidosis, by the date of publication
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CR=Complete Response, PHR = Partial Hematologic Response.It is important to know that 43% of the patients
with amyloidosis, who are treated with lenalidomide,
may develop skin rashes. The rashes are characterized
as morbilliform, urticarial, dermatitic, acneiform, and
undefined. Severe rashes require permanent discon-
tinuation of lenalidomide [19].
This unique reported case of AL amyloidosis pre-
sented with hemorrhagic bullous skin lesions, high levels
of light chain protein only, presence of t(11,14) by cyto-
genic study, overexpression of cyclin D1, and only partial
response to the standard multiple myeloma regimen,
which includes lenalidomide and bortezomib, and dexa-
methasone (RVD). All these features represent a poor
prognosis [20-22]. A more aggressive treatment ap-
proach with combination of five agents resulted in
achieving meaningful success. This included combin-
ation of lenalidomide, bortezomib, liposomal doxorubi-
cin, cyclophosphamide, and dexamethasone. The overall
response included a very good partial response (VGPR),
associated with a great than 90% reduction in the
kappa light chain level, and complete resolution of the
breast skin lesions. This case illustrates that bullous
hemorrhagic skin lesions, associated with primary sys-
temic amyloidosis may need more aggressive treatment
such as the five-drug combination that we have used.eatment of dermatologic manifestations of systemic AL
ference Published Year Treatment Outcomes
m Acad Dermatol) 1980 Melphalan+ Prednisone No Clinical
CR, 9 mo
rit J Dermatol) 1985 Dapson/Prednisone CR




UTIS) 1989 Prednisone +
Azathioprine
Treatment failed
tern J Dermatol) 1990 Cochicine +DMSO Partial response
edicine) 1993 Alkylating Agents Poor Response
r J. Med) 2000 Dexamethasone
Stabilized after 3 cycles
Cutan Pathol) 2001 CHOP —
lood) 2002 Melphalane+ASCT 100-day mortality
of 21-39 %
m J Medicine) 2002 ASCT Treatment-related
Mortality of 14 %
rit J Haem) 2006 HD chemotherapy +
100-day mortality ASCT
23 %
2nd ASH Meeting) 2010 Lenalidomide +
Dexamethasone
Mortality 13 %
No CR, PHR 41 %,
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